# Continuation of The Collaborative Islet Transplantation Registry (CITR)

> **NIH NIH U01** · THE EMMES COMPANY, LLC · 2024 · $314,470

## Abstract

PROJECT SUMMARY
This application, in response to RFA-DK-21-013, describes a comprehensive Data and Statistical Coordinating
Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) for 2022-2027. Continuing from 2017-2021
as the CITR-DSCC, Emmes continues to collaborate with the NIDDK Program Office, the Oversight Committee,
and the CITR investigators to support the established CITR Registry. The registry includes allogeneic and
autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be
followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic
episodes in persons with Type 1 diabetes or lacking pancreatic islets for any reason including therapeutic
pancreatectomy or any loss of islet cell function. For more details, please see the Specific Aims section.

## Key facts

- **NIH application ID:** 10903933
- **Project number:** 5U01DK133709-03
- **Recipient organization:** THE EMMES COMPANY, LLC
- **Principal Investigator:** Elizabeth Holly Payne
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $314,470
- **Award type:** 5
- **Project period:** 2022-09-15 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10903933

## Citation

> US National Institutes of Health, RePORTER application 10903933, Continuation of The Collaborative Islet Transplantation Registry (CITR) (5U01DK133709-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10903933. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*